Using the SpiroGym app to improve cough strength in Parkinson's patients
Effect of the SpiroGym App on Voluntary Cough Strength in Parkinson's Disease
This study is testing if using the SpiroGym app can help people with Parkinson's disease improve their cough strength better than traditional methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | General University Hospital, Prague Academic / other |
| Locations | 1 site (Prague) |
| Trial ID | NCT06481540 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates the effectiveness of the SpiroGym app in enhancing expiratory muscle strength training (EMST) for patients with Parkinson's disease. Participants will undergo a double-blind, randomized controlled trial where one group will receive EMST with the SpiroGym app, which provides visual feedback, while the control group will receive EMST without the app. The primary goal is to determine if the app's feedback leads to greater improvements in voluntary peak cough flow over 8 and 24 weeks. The study builds on previous findings that suggest the app can significantly enhance cough strength in a shorter timeframe compared to traditional methods.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Parkinson's disease who are on stable dopaminergic medication.
Not a fit: Patients with other neurological disorders, significant cognitive impairment, or uncontrolled breathing issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved cough strength and respiratory health for patients with Parkinson's disease.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Parkinsons disease * Stable dopaminergic medication (stable dose for at least 1 month) Exclusion Criteria: * Other neurological disorders * Difficulty complying due to neuropsychological dysfunction (dementia with a score of less - - than 19 on the Montreal Cognitive Assessment) * Breathing disorders or diseases * Smoking in the past 5 years * Uncontrolled hypertension
Where this trial is running
Prague
- General University Hospital — Prague, Czechia (Recruiting)
Study contacts
- Study coordinator: Martin Srp, PhD
- Email: martin.srp@vfn.cz
- Phone: +420224965513
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.